AstraZeneca plc goes ‘nuclear’ on R&D spend to double sales

Pharmaceuticals giant AstraZeneca plc (LON: AZN) could transform itself with an ambitious development drive.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shrinking pharmaceutical giant AstraZeneca’s (LSE: AZN) chief executive Pascal Soriot is on record as saying he had no choice but to overhaul the company when he took over in October 2012 because “the company was imploding” due to the number of patents expiring around the same time.

The truth of that statement is plain to see — revenue and earnings fell just about every year since 2012 and look set to continue falling during 2016 and 2017. Between 2011 and 2017, City analysts expect around $17bn to have been lost from annual sales.

Ambitious turnaround plan

However, Mr Soriot is cutting deep into AstraZeneca’s culture, its bloated workforce, and the firm’s economics in the belief that such radical surgery will transform the company into a speciality drugs supplier focused on treatments for cancer, respiratory and cardiovascular diseases, and similar areas that have potential to drive future sales. That’s in contrast to the mass-market approach that fuelled AstraZeneca’s previous ascendancy, but which is now losing its wheels.

Thousands of redundancies over the last three years precede more to come — painful but necessary, and an indication of how the firm is bearing down on selling, general and administrative costs. Meanwhile, research and development (R&D) spend runs at around 24% of sales, which is a figure that exceeds the industry average. Spending on R&D can be a good forward indicator for investors. A sustained programme of R&D investment often creates real value that could pay dividends down the line.

Targeting talent

The bold centrepiece of Mr Pascal’s master plan for AstraZeneca is the new $500m corporate headquarters and research hub the firm is building near Cambridge. It aims to attract top brains from Britain’s best university labs to enable ground-up research to drive AstraZeneca’s forward growth. That kind of initiative seems to be what many have been crying out for — it’s just what Britain and AstraZeneca need to help commercialise the country’s raw talent. This move could prove to be a masterstroke that powers the company’s comeback.

The firm has already shifted around a quarter of its UK workforce into rented accommodation around Cambridge to work closely with academic researchers. Mr Soriot thinks his game plan has great potential and said two years ago that he expected sales to rise to $45bn by 2023. That would be a more-than-90% increase over the $23.6bn the firm achieved during 2015 and would work wonders for the company’s share price.

AstraZeneca has gone ‘nuclear’ on R&D which, along with a lively bolt-on acquisition programme, seems set to rejuvenate the firm’s product pipeline. AstraZeneca oozes potential right now, and investors can hop aboard for a forward price-to-earnings rating of just over 14 at today’s 3,876p share price. That strikes me as a reasonable price, and there’s a 5% forward dividend yield to keep us warm while we wait.                                                               

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »